

Results for announcement to the market		
Name of issuer	Rua Bioscience Ltd	
Reporting Period	6 months to 31 st December 2021	
Previous Reporting Period	6 months to 31 st December 2020	
Currency		
	Amount (000s)	Percentage change
Revenue from continuing operations	\$360	34%
Total Revenue	\$360	34%
Net profit/(loss) from continuing operations	(\$2,465)	(6%)
Total net profit/(loss)	(\$2,465)	(6%)
Interim/Final Dividend		
Amount per Quoted Equity Security	None	
Imputed amount per Quoted Equity Security	Not Applicable	
Record Date	Not Applicable	
Dividend Payment Date	Not Applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.16	\$0.18
A brief explanation of any of the figures above necessary to enable the figures to be understood	Net tangible asset per share is calculated by dividing net assets less intangible assets by the total shares on issue at the end of the period.	
Authority for this announcement		
Name of person authorised to make this announcement	Rob Mitchell	
Contact person for this announcement	Kerry Donovan	
Contact phone number	+64 (21) 128 7689	
Contact email address	kerry.donovan@ruabio.com	
Date of release through MAP	25/01/2022	

Unaudited financial statements accompany this announcement.